ArticleClinics (Sao Paulo, Brazil)2026
Superiority of the ROMA index over HE4 and CA125 for diagnosing ovarian cancer in a Bangladeshi cohort.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is a leading cause of mortality among women globally. This study aimed to evaluate the diagnostic value of CA-125, HE4, and the ROMA index in identifying ovarian cancer in patients in Bangladesh.
methodsThis case-control study was conducted at the National Institute of Cancer Research and Hospital (NICRH) in 50 patients with histologically confirmed epithelial ovarian cancer, 25 patients with benign ovarian diseases, and 25 healthy controls. Women with prior chemotherapy or hormonal therapy, non-epithelial ovarian cancer, bilateral oophorectomy, pregnancy, or serious systemic illness were excluded. Serum CA-125 and HE4 levels were measured using Chemiluminescence Immunoassay (CLIA), and the ROMA index was calculated. Receiver Operating Characteristic (ROC) analysis was performed to assess diagnostic performance.
resultsThe mean ages of participants were 52.5-years for ovarian cancer patients, 38.2-years for those with benign diseases, and 45.0-years for healthy controls. The median serum levels of HE4, CA-125, and ROMA index were significantly higher in ovarian cancer patients compared to controls. ROC analysis revealed AUCs of 0.95 for ROMA, 0.92 for HE4, and 0.88 for CA-125 in differentiating cancer from healthy controls, and 0.93 for ROMA, 0.94 for HE4, and 0.60 for CA-125 in differentiating cancer from benign ovarian diseases. ROMA and HE4 significantly distinguished ovarian cancer from benign conditions (p < 0.001), while CA-125 did not (p = 0.165).
conclusionIn this study, the ROMA index appeared to perform better than HE4 and CA-125, though findings should be interpreted cautiously, considering the limited statistical power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.